KALA
HEALTHCAREKala Pharmaceuticals Inc
$0.12+0.00 (+2.68%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving KALA Today?
No stock-specific AI insight has been generated for KALA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.08$20.60
$0.12
Fundamentals
Market Cap$107M
P/E Ratio—
EPS$-3.31
Dividend Yield—
Dividend / Share—
ROE-2.8%
Profit Margin—
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding929.5M
KALA News
20 articles- KALA BIO Announces Reverse Stock SplitYahoo Finance·May 7, 2026
- Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to AdjustmentsYahoo Finance·Apr 28, 2026
- Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic MedicineYahoo Finance·Apr 21, 2026
- Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development OpportunitiesYahoo Finance·Apr 1, 2026
- KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now LiveYahoo Finance·Mar 30, 2026
- Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug CandidateYahoo Finance·Mar 18, 2026
- Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug CandidateYahoo Finance·Mar 18, 2026
- Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research AgentsYahoo Finance·Mar 11, 2026
- BC-Most Active StocksYahoo Finance·Mar 11, 2026
- Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution AcceleratesYahoo Finance·Mar 11, 2026
- Stock Trend Capital Provides Younet AI Investment UpdateYahoo Finance·Mar 9, 2026
- KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”Yahoo Finance·Mar 4, 2026
- KALA BIO Settles Approximately $10.6 million of DebtYahoo Finance·Jan 5, 2026
- KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesYahoo Finance·Dec 5, 2025
- KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesYahoo Finance·Dec 4, 2025
- Top Midday GainersYahoo Finance·Dec 1, 2025
- KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. LazarYahoo Finance·Dec 1, 2025
- KALA BIO: Q3 Earnings SnapshotYahoo Finance·Nov 19, 2025
- KALA Stock Crashes 88% in a Month Following Eye Disorder Study FailureYahoo Finance·Oct 8, 2025
- Top Midday DeclinersYahoo Finance·Sep 30, 2025
All 20 articles loaded
Price Data
Open$0.11
Previous Close$0.11
Day High$0.12
Day Low$0.10
52 Week High$20.60
52 Week Low$0.08
52-Week Range
$0.08$20.60
$0.12
Fundamentals
Market Cap$107M
P/E Ratio—
EPS$-3.31
Dividend Yield—
Dividend / Share—
ROE-2.8%
Profit Margin—
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding929.5M
About Kala Pharmaceuticals Inc
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of therapies using its proprietary nanoparticle-based mucus penetrating particle (MPP) technology for the treatment of eye diseases. The company is headquartered in Watertown, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—